Glafomin M Tablet 1/500 mg

Adult dose

This medication is administered 1 to 2 times a day before meals or with meals. The dose can be adjusted according to the current treatment regimen, efficacy, and tolerance of each patient, with appropriate blood glucose monitoring. Typically, treatment starts at a low dose, and the dose can be adjusted based on the patient's current medications and blood glucose levels. In clinical trials, the initial daily dose was Metformin Hydrochloride/Glymepride 2mg/500mg.

This medication can cause severe lactic acidosis or hypoglycemia, so it should be temporarily discontinued and discussed with a doctor in cases of rapidly declining kidney function or dehydration symptoms. This medication should not be used in patients with a kidney function below 45 mL/min/1.73 m², and elderly patients or those taking medications that affect kidney function should have their kidney function regularly monitored. As it may increase the risk of cardiovascular disease, cardiovascular status should be carefully monitored while taking this medication. This medication should not be given to patients with insulin-dependent diabetes, acute metabolic acidosis, severe liver dysfunction, pregnant or breastfeeding women, and certain renal impairments. Patients at high risk for hypoglycemia, those with poor nutritional status or irregular eating habits, and those consuming excessive alcohol should use this medication with special caution. Adverse reactions such as gastrointestinal disturbances, allergic reactions, blood abnormalities, or vitamin B12 deficiency may occur while taking this medication, so symptoms should be reported to a doctor or pharmacist immediately. This medication may interact with other drugs, so healthcare providers must be informed of any concomitant medications, especially those that affect kidney function. Pregnant or breastfeeding women should not take this medication, and switching to insulin therapy is recommended if necessary. When administering to children or the elderly, careful observation and dose adjustments are necessary. Regular monitoring of blood glucose levels is required, and medical staff should be informed immediately of symptoms of hypoglycemia or lactic acidosis. Caution is needed while driving or operating machinery, and it should be stored out of reach of children.

Serious side effects

Hives, severe swelling (edema), difficulty breathing, severe thrombocytopenic purpura with thrombocytopenia, liver abnormalities (jaundice), hepatic failure, severe allergic reactions, severe edema or urinary abnormalities, sudden and very severe headache, confusion, paralysis, cardiac arrest, hypoglycemia, lactic acidosis, severe allergic reactions, liver failure, specific changes in blood values, severe hypoglycemia, thrombocytopenia, hemolytic anemia, acute renal failure.

Mild side effects

Diarrhea, nausea, vomiting, abdominal distension, loss of appetite, indigestion, constipation, abdominal pain, visual impairment related to changes in blood sugar levels, taste disturbance, erythema, itching, rash, metallic taste, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, agranulocytosis, pancytopenia, vitamin B12 deficiency, increased hepatic enzymes, hepatic impairment, hepatitis, allergic vasculitis, photosensitivity, hyponatremia, hypothyroidism

This medication should be stored in a tightly closed container to prevent air or moisture from entering. The storage temperature should ideally be maintained at room temperature between 1 to 30 degrees Celsius.

Appearance

Light pink oblong film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)